KIR2DS4 AND ITS VARIANT KIR1D ARE ASSOCIATED WITH AGVHD, CMV AND OS AFTER SIBING RELATED HLA MATCHED TRANSPLANTATION FOR PATIENTS WHOSE DONORS BELONG TO KIR GENE HAPLOTYPE A
(Abstract release date: 05/21/15)
EHA Library. Wu X. 06/13/15; 103052; S442
Xiaojin Wu
Contributions
Contributions
Abstract
Abstract: S442
Type: Oral Presentation
Presentation during EHA20: From 13.06.2015 11:45 to 13.06.2015 12:00
Location: Room C2
Background
Hematopoietic stem cell transplantation (HSCT) outcomes of donor and recipient KIR genotypes have been extensively studies. However, the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation has not been explored.
Aims
To the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation.
Methods
To study this, 165 patients transplanted from KIR gene haplotype A were genotyped and divided into three groups: 2DS4+/1D- (two intact KIR2DS4 alleles), 2DS4+/1D+ (heterozygous), 1D+/1D+ (homozygous for the deletion variant KIR1D). No difference of the recovery of neutrophils and platelets was observed in the three groups.
Results
The cumulative incidences of Grade ?-? acute GVHD were 28.94%, 14.11% and 44.44%, respectively, in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups within day+100 (P=0.0159). Multivariate analysis identified 1D+/1D+ was an independent risk factor for aGVHD (HR= 4.221, 95%CI 1.470-12.124, P=0.007). In contrast, the cumulative incidences of chronic GVHD, 3-year cumulative relapse, and treatment-related mortality displayed no significant difference. The rate of CMV reactivation were 46.96%, 20.16% and 53.25% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups (P=0.0017). Multivariate analysis identified 2DS4+/1D+ was an independent protective factor for CMV reactivation (HR=0.268, 95%CI 0.125-0.574, P=0.001). Although the overall survival (OS) showed no difference in the first year, the OS of 2DS4+/1D- group showed a significant superiority over the other groups after one year (P=0.0361). In the disease stage of advanced patients, the 3-year probability of DFS were 51.06%, 34.01 % and 0% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ group (P=0.0314).
Summary
Collectively, our data suggest that the KIR 2DS4/1D allelic variance is associated with the outcome of sibling related HLA matched HSCT, and donor subclassification of KIR 2DS4/1D alleles should be consider in this setting.
Keyword(s): HLA mismatched, KIR, Sibling, Transplant
Session topic: Stem cell transplantation: Clinical 2
Type: Oral Presentation
Presentation during EHA20: From 13.06.2015 11:45 to 13.06.2015 12:00
Location: Room C2
Background
Hematopoietic stem cell transplantation (HSCT) outcomes of donor and recipient KIR genotypes have been extensively studies. However, the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation has not been explored.
Aims
To the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation.
Methods
To study this, 165 patients transplanted from KIR gene haplotype A were genotyped and divided into three groups: 2DS4+/1D- (two intact KIR2DS4 alleles), 2DS4+/1D+ (heterozygous), 1D+/1D+ (homozygous for the deletion variant KIR1D). No difference of the recovery of neutrophils and platelets was observed in the three groups.
Results
The cumulative incidences of Grade ?-? acute GVHD were 28.94%, 14.11% and 44.44%, respectively, in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups within day+100 (P=0.0159). Multivariate analysis identified 1D+/1D+ was an independent risk factor for aGVHD (HR= 4.221, 95%CI 1.470-12.124, P=0.007). In contrast, the cumulative incidences of chronic GVHD, 3-year cumulative relapse, and treatment-related mortality displayed no significant difference. The rate of CMV reactivation were 46.96%, 20.16% and 53.25% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups (P=0.0017). Multivariate analysis identified 2DS4+/1D+ was an independent protective factor for CMV reactivation (HR=0.268, 95%CI 0.125-0.574, P=0.001). Although the overall survival (OS) showed no difference in the first year, the OS of 2DS4+/1D- group showed a significant superiority over the other groups after one year (P=0.0361). In the disease stage of advanced patients, the 3-year probability of DFS were 51.06%, 34.01 % and 0% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ group (P=0.0314).
Summary
Collectively, our data suggest that the KIR 2DS4/1D allelic variance is associated with the outcome of sibling related HLA matched HSCT, and donor subclassification of KIR 2DS4/1D alleles should be consider in this setting.
Keyword(s): HLA mismatched, KIR, Sibling, Transplant
Session topic: Stem cell transplantation: Clinical 2
Abstract: S442
Type: Oral Presentation
Presentation during EHA20: From 13.06.2015 11:45 to 13.06.2015 12:00
Location: Room C2
Background
Hematopoietic stem cell transplantation (HSCT) outcomes of donor and recipient KIR genotypes have been extensively studies. However, the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation has not been explored.
Aims
To the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation.
Methods
To study this, 165 patients transplanted from KIR gene haplotype A were genotyped and divided into three groups: 2DS4+/1D- (two intact KIR2DS4 alleles), 2DS4+/1D+ (heterozygous), 1D+/1D+ (homozygous for the deletion variant KIR1D). No difference of the recovery of neutrophils and platelets was observed in the three groups.
Results
The cumulative incidences of Grade ?-? acute GVHD were 28.94%, 14.11% and 44.44%, respectively, in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups within day+100 (P=0.0159). Multivariate analysis identified 1D+/1D+ was an independent risk factor for aGVHD (HR= 4.221, 95%CI 1.470-12.124, P=0.007). In contrast, the cumulative incidences of chronic GVHD, 3-year cumulative relapse, and treatment-related mortality displayed no significant difference. The rate of CMV reactivation were 46.96%, 20.16% and 53.25% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups (P=0.0017). Multivariate analysis identified 2DS4+/1D+ was an independent protective factor for CMV reactivation (HR=0.268, 95%CI 0.125-0.574, P=0.001). Although the overall survival (OS) showed no difference in the first year, the OS of 2DS4+/1D- group showed a significant superiority over the other groups after one year (P=0.0361). In the disease stage of advanced patients, the 3-year probability of DFS were 51.06%, 34.01 % and 0% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ group (P=0.0314).
Summary
Collectively, our data suggest that the KIR 2DS4/1D allelic variance is associated with the outcome of sibling related HLA matched HSCT, and donor subclassification of KIR 2DS4/1D alleles should be consider in this setting.
Keyword(s): HLA mismatched, KIR, Sibling, Transplant
Session topic: Stem cell transplantation: Clinical 2
Type: Oral Presentation
Presentation during EHA20: From 13.06.2015 11:45 to 13.06.2015 12:00
Location: Room C2
Background
Hematopoietic stem cell transplantation (HSCT) outcomes of donor and recipient KIR genotypes have been extensively studies. However, the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation has not been explored.
Aims
To the association of KIR2DS4 and its variant KIR1D with outcomes in patients who transplanted from a donor for KIR haplotye A after sibing related HLA matched transplantation.
Methods
To study this, 165 patients transplanted from KIR gene haplotype A were genotyped and divided into three groups: 2DS4+/1D- (two intact KIR2DS4 alleles), 2DS4+/1D+ (heterozygous), 1D+/1D+ (homozygous for the deletion variant KIR1D). No difference of the recovery of neutrophils and platelets was observed in the three groups.
Results
The cumulative incidences of Grade ?-? acute GVHD were 28.94%, 14.11% and 44.44%, respectively, in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups within day+100 (P=0.0159). Multivariate analysis identified 1D+/1D+ was an independent risk factor for aGVHD (HR= 4.221, 95%CI 1.470-12.124, P=0.007). In contrast, the cumulative incidences of chronic GVHD, 3-year cumulative relapse, and treatment-related mortality displayed no significant difference. The rate of CMV reactivation were 46.96%, 20.16% and 53.25% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ groups (P=0.0017). Multivariate analysis identified 2DS4+/1D+ was an independent protective factor for CMV reactivation (HR=0.268, 95%CI 0.125-0.574, P=0.001). Although the overall survival (OS) showed no difference in the first year, the OS of 2DS4+/1D- group showed a significant superiority over the other groups after one year (P=0.0361). In the disease stage of advanced patients, the 3-year probability of DFS were 51.06%, 34.01 % and 0% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ group (P=0.0314).
Summary
Collectively, our data suggest that the KIR 2DS4/1D allelic variance is associated with the outcome of sibling related HLA matched HSCT, and donor subclassification of KIR 2DS4/1D alleles should be consider in this setting.
Keyword(s): HLA mismatched, KIR, Sibling, Transplant
Session topic: Stem cell transplantation: Clinical 2
{{ help_message }}
{{filter}}